Rasmussen B

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Tobiasson M, Pandzic T, Illman J, ..., Dybedal I, Hellström-Lindberg E

J Clin Oncol 42 (12) 1378-1390 [2024-04-20; online 2024-01-17]

Clinical Genomics Uppsala [Collaborative]

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

Rasmussen B, Göhring G, Bernard E, ..., Möllgård L, Hellström-Lindberg E

Leukemia 36 (5) 1436-1439 [2022-05-00; online 2022-03-11]

Clinical Genomics Uppsala [Collaborative]